Actinium’s HuM195 mAb is being tested for treatment of myeloid leukemia.
PacificGMP will manufacture and perform fill/finish of Actinium Pharmaceuticals’ HuM195 monoclonal antibody for a Phase I/II clinical trial. A stability study of the final product will also be conducted. HuM195 is a monoclonal antibody that is currently being tested in a Phase I clinical trial to treat acute myeloid leukemia.

Previous articleNational Neurovision Research Institute to Fund Evaluation of Resolvyx Pharmaceuticals’ Eye Disease Therapeutics
Next articleNew Insights Gained on How Calpain Enzymes Are Regulated